Entry4.74→Now4.66
AQST staged catalysts drive multi-year upside Open original source
AQST Aquestive Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:24
Sep 12
Sep 12
AQST staged catalysts drive multi-year upside
The author is bullish on AQST, mapping a sequence of regulatory and commercial catalysts to escalating price levels. Anaphylm resubmission acceptance (late Q3/early Q4 '26) is seen driving $5.50-$6.00, FDA filing and clock-setting pushing $6.50-$7.25, and eventual Anaphylm US approval in '27 reaching $12-$16. Further catalysts include Canada NDS filing, Libervant US deal or solo launch, age-expansion PR, EU MAA filing, and AQST-108 data, with the author expecting high-teens to $20s on 7-product royalties and insurance uptake. Main risk is that these are speculative targets dependent on regulatory and commercial execution.
HIGH
00:56
Jan 17
Jan 17
Aquestive FDA uncertainty, no new buys.
FDA deficiencies create major uncertainty and lower confidence, but holders should not sell after the crash because approval and overseas opportunities remain possible; non-owners have no reason to buy.
MED
About AQST Investor Commentary
Across the available history and selected sources, Buzzberg tracks AQST (Aquestive Therapeutics, Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/Efficient-Two-5030, Jim Cramer.